Program
Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049
Its studies are mostly in Colorectal Neoplasms, led by Boehringer Ingelheim.
Drug pageAnti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 1, since Feb 11, 20213 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 30 open or running | phase 1since Feb 11, 2021 | Feb 11, 2021 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 11, 2021First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT04752215 · 67 enrolled · United States, Canada
- Oct 16, 2023Phase 1 study in Gastrointestinal NeoplasmsNCT06091930 · 21 enrolled · Japan
- Mar 17, 2025Phase 1 study in Colorectal NeoplasmsNCT06882746 · 14 enrolled · United States, Germany, Spain
TargetBeta
“An immunoglobulin G (IgG)-like bispecific T-cell engaging antibody directed against both natural cytotoxicity triggering receptor 3 ligand 1 (NCR3LG1; B7-H6) and T-cell surface antigen CD3, ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06882746Colorectal Neoplasms · United States, Germany, Spain | 1 | Terminated | Sep 8, 2026 | 14 |
| NCT06091930Gastrointestinal Neoplasms · Japan | 1 | Terminated | Aug 15, 2025 | 21 |
| NCT04752215Colorectal Neoplasms · United States, Canada | 1 | Completed | Nov 19, 2024 | 67 |
How it is read
Names in the registry
- “BI 765049”, 3 entries
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.